NEWTON-CABG beyond intensive LDL-C lowering: where do we turn to prevent vein graft disease?

Coronary artery bypass grafting (CABG) remains a keystone in the management of advanced coronary artery disease. However, the long-term success of CABG remains limited by saphenous vein graft (SVG) failure—an often indispensable conduit in many patients—as its maladaptive biological processes drive thrombosis, neointimal hyperplasia, and accelerated atherosclerosis, leading to recurrent ischaemia and adverse events. While intensive low-density lipoprotein cholesterol (LDL-C) lowering with statins is an established pillar of secondary prevention and was suggested by earlier trials to improve graft patency, a critical gap in evidence remained: whether initiating early, perioperative, extremely intensive LDL-C reduction beyond that achieved with high-intensity statins alone could prevent the early structural failure of the vein grafts. The NEWTON-CABG trial (NCT03900026), a rigorous multinational study, was designed to address this precise unmet need, investigating the potential of the PCSK9 inhibitor evolocumab, initiated immediately after CABG, to improve SVG patency through profound LDL-C lowering in patients already receiving guideline-directed statin therapy.1 Despite achieving a profound reduction in LDL-C, evolocumab did not lead to a significant improvement in 24-month graft patency compared to placebo.1 The authors suggest that thrombosis and intimal hyperplasia, rather than early atherosclerosis, may drive early vein graft failure. These findings underscore the distinct, complex pathophysiology of CABG, and the need to investigate specific therapeutic targets.